Research Type: Assessment


Apr 2022 | Assessment

Interventions of Interest: casirivimab/imdevimab (Ronapreve™, Regeneron) sotrovimab (GlaxoSmithKline and Vir Biotechnology) molnupiravir (Merck) PF-07321332/ritonavir (Pfizer) fluvoxamine (Investigator initiated) ICER is currently conducting a special assessment of outpatient treatments for COVID-19. COVID-19 is an infectious respiratory disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. As of August 2021, there have been over […]

Chemotherapy-Induced Neutropenia

Apr 2022 | Assessment

Interventions of Interest: plinabulin (BeyondSpring Pharmaceuticals) trilaciclib (Cosela™, G1 Therapeutics) Until recently, cytotoxic chemotherapy was the primary form of chemotherapy used to treat cancer, and it remains in widespread use today. Because it targets rapidly dividing cells, one of the common side effects of cytotoxic chemotherapy is low blood cell counts (myelosuppression), including low neutrophil […]

Diabetes: Type 2

Jan 2022 | Assessment

Interventions of Interest: tirzepatide (Eli Lilly) More than 34 million Americans, or 10% of the US population, have diabetes mellitus. Type 2 diabetes mellitus (T2DM), which is characterized by progressive loss of adequate insulin secretion from the pancreas and peripheral resistance to insulin, accounts for 90-95% of those cases. Prevalence of T2DM increases with age […]


Nov 2021 | Assessment

Interventions of Interest: Tezepelumab (Amgen, AstraZeneca) The Centers for Disease Control and Prevention (CDC) estimates that 25 million Americans have asthma of whom 5 million are children. Asthma causes the airways of the lungs to narrow or become blocked, making it hard to breathe. Many processes contribute to the narrowing, including tightening of the muscles […]

Hypertrophic Cardiomyopathy

Oct 2021 | Assessment

Interventions of Interest: Mavacamten (MyoKardia and Bristol-Myers Squibb) Hypertrophic cardiomyopathy (HCM) is a disorder of the heart due to dysfunction of the sarcomeres in cardiac muscle cells (myocytes). Sarcomeres are cellular structures that are critical in myocyte contraction. The sarcomere dysfunction in HCM can lead to hypertrophy (thickening) of the heart. HCM can be due […]

Myasthenia Gravis

Sep 2021 | Assessment

Interventions of Interest: Eculizumab (Soliris®, Alexion Pharmaceuticals, Inc.) Efgartigimod (Argenx, Halozyme Therapeutics, and Zai Lab) Myasthenia gravis is a rare chronic autoimmune disorder in which the immune system produces antibodies that prevent acetylcholine from binding with acetylcholine receptors, ultimately resulting in muscle contraction. For more information, please contact Maggie O’Grady, Program Manager, at View the Key […]

Atopic Dermatitis

Jul 2021 | Assessment

Interventions of Interest: abrocitinib (Pfizer) tralokinumab (Adtralza®, LEO Pharma) baricitinib (Olumiant®, Eli Lilly, Incyte Corporation) upadacitinib (Rinvoq®, AbbVie) ruxolitinib (Opzelura™, Incyte Corporation) Atopic dermatitis is a chronic relapsing skin condition associated with dry skin and itching. It is characterized by acute flare-ups of pruritic lesions over dry skin. Atopic dermatitis is a subset of the […]

Cardiovascular Disease: Atherosclerosis

Oct 2018 | Assessment

In June 2018, ICER announced its intention to assess the comparative clinical effectiveness and value of canakinumab (Novartis) for cardiovascular risk reduction in people with atherosclerosis. However, in October 2018, when the Food and Drug Administration declined to approve canakinumab’s expanded indication for atherosclerotic cardiovascular disease, ICER announced it would no longer proceed with its value assessment. […]

Opioid Epidemic: Abuse Deterrent Opioids

Jul 2017 | Assessment

Interventions of Interest: Hysingla® ER (Hydrocodone, Purdue) Vantrela® (Hydrocodone , Teva) Arymo® ER ( Morphine, Egalet) Embeda® (Morphine + naltrexone, Pfizer) Morphabond® (Morphine extended release, Inspirion Delivery Technologies) OxyContin® TR (Oxycodone, Purdue) Xtampza®ER (Oxycodone, Collegium Pharmaceutical Inc) Targiniq® (Oxycodone + naloxone extended release, Purdue) Troxyca® ER (Oxycodone + naltrexone, Pfizer) RoxyBond® (Oxycodone, Inspirion Delivery Technologies) […]

Ovarian Cancer

Sep 2017 | Assessment

Interventions of Interest: Rucaparib (Rubraca®, Clovis Oncology) Niraparib (Zejula®, Tesaro, Inc.) Olaparib (Lynparza®, AstraZeneca) ICER’s report reviews evidence on the comparative clinical effectiveness and value of poly (ADP-ribose) polymerase (PARP) inhibitors for treatment of ovarian cancer. During the public meeting the Midwest CEPAC voted on key questions related to the clinical effectiveness and value of the […]